Entrada Therapeutics (TRDA) Retained Earnings: 2022-2025
Historic Retained Earnings for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$233.9 million.
- Entrada Therapeutics' Retained Earnings fell 79.26% to -$233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$233.9 million, marking a year-over-year decrease of 79.26%. This contributed to the annual value of -$129.3 million for FY2024, which is 33.66% up from last year.
- As of Q3 2025, Entrada Therapeutics' Retained Earnings stood at -$233.9 million, which was down 23.25% from -$189.8 million recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' Retained Earnings registered a high of -$115.3 million during Q1 2022, and its lowest value of -$233.9 million during Q3 2025.
- For the 3-year period, Entrada Therapeutics' Retained Earnings averaged around -$174.0 million, with its median value being -$185.4 million (2023).
- Per our database at Business Quant, Entrada Therapeutics' Retained Earnings spiked by 47.29% in 2024 and then tumbled by 79.26% in 2025.
- Over the past 4 years, Entrada Therapeutics' Retained Earnings (Quarterly) stood at -$188.3 million in 2022, then decreased by 3.55% to -$195.0 million in 2023, then spiked by 33.66% to -$129.3 million in 2024, then plummeted by 79.26% to -$233.9 million in 2025.
- Its last three reported values are -$233.9 million in Q3 2025, -$189.8 million for Q2 2025, and -$146.7 million during Q1 2025.